Rocket Pharmaceuticals CFO Aaron Ondrey Steps Down to Pursue New Opportunities
PorAinvest
martes, 26 de agosto de 2025, 1:13 am ET1 min de lectura
RCKT--
Ondrey joined Rocket Pharmaceuticals in March 2024 and served as the CFO until his resignation. His total compensation for 2024 was approximately $3 million [3]. Wilson, who joined the company as General Counsel and Chief Compliance Officer in November 2021 and became Chief Corporate Officer in March 2024, will take over the interim PFO role [3].
The resignation of Ondrey comes amidst significant developments for Rocket Pharmaceuticals. The company's pivotal Phase 2 trial of RP-A501 for Danon disease had a clinical hold lifted by the FDA in late July 2025 [2]. The FDA's decision to resume the trial, following a recalibrated dose and revised protocol, is a positive development for the company and its stock [2].
Rocket Pharmaceuticals' stock, RCKT, saw a 33.68% increase during the premarket session on Wednesday, August 25, 2025, following the FDA's decision [2]. The stock was trading at $3.91 at the time, indicating investor confidence in the company's progress.
The changes in Rocket Pharmaceuticals' leadership and the FDA's decision on the pivotal trial are significant developments for the company. Investors should closely monitor these developments for potential impacts on the company's financial performance and stock price.
References:
[1] https://www.tipranks.com/news/the-fly/rocket-pharmaceuticals-cfo-aaron-ondrey-resigns-to-pursue-other-opportunities-thefly
[2] https://www.benzinga.com/news/fda/25/08/47233429/fda-lifts-rocket-pharmaceuticals-study-hold-for-rare-disease-gene-therapy
[3] https://www.marketwatch.com/story/rocket-pharmaceuticals-cfo-aaron-ondrey-resigns-0a7dd960
Rocket Pharmaceuticals' CFO Aaron Ondrey resigned on August 20, 2025, to pursue other opportunities, with his last day being September 5, 2025. Martin Wilson, the company's General Counsel and Chief Corporate Officer, was appointed interim Principal Financial Officer on August 25, 2025, effective September 8, 2025.
Rocket Pharmaceuticals (RCKT) announced the resignation of its Chief Financial Officer (CFO), Aaron Ondrey, effective September 5, 2025. Ondrey will pursue other opportunities, as per a regulatory filing [1]. Martin Wilson, the company's General Counsel and Chief Corporate Officer, has been appointed as the interim Principal Financial Officer (PFO), effective September 8, 2025 [1].Ondrey joined Rocket Pharmaceuticals in March 2024 and served as the CFO until his resignation. His total compensation for 2024 was approximately $3 million [3]. Wilson, who joined the company as General Counsel and Chief Compliance Officer in November 2021 and became Chief Corporate Officer in March 2024, will take over the interim PFO role [3].
The resignation of Ondrey comes amidst significant developments for Rocket Pharmaceuticals. The company's pivotal Phase 2 trial of RP-A501 for Danon disease had a clinical hold lifted by the FDA in late July 2025 [2]. The FDA's decision to resume the trial, following a recalibrated dose and revised protocol, is a positive development for the company and its stock [2].
Rocket Pharmaceuticals' stock, RCKT, saw a 33.68% increase during the premarket session on Wednesday, August 25, 2025, following the FDA's decision [2]. The stock was trading at $3.91 at the time, indicating investor confidence in the company's progress.
The changes in Rocket Pharmaceuticals' leadership and the FDA's decision on the pivotal trial are significant developments for the company. Investors should closely monitor these developments for potential impacts on the company's financial performance and stock price.
References:
[1] https://www.tipranks.com/news/the-fly/rocket-pharmaceuticals-cfo-aaron-ondrey-resigns-to-pursue-other-opportunities-thefly
[2] https://www.benzinga.com/news/fda/25/08/47233429/fda-lifts-rocket-pharmaceuticals-study-hold-for-rare-disease-gene-therapy
[3] https://www.marketwatch.com/story/rocket-pharmaceuticals-cfo-aaron-ondrey-resigns-0a7dd960
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
Comentarios
Aún no hay comentarios